{"nctId":"NCT00118404","briefTitle":"Cognitive Therapy for Recurrent Depression","startDateStruct":{"date":"2000-03"},"conditions":["Depression"],"count":523,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Behavioral: Continuation phase cognitive therapy","Behavioral: Acute phase cognitive therapy"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Continuation phase pill placebo","Behavioral: Acute phase cognitive therapy"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Continuation phase fluoxetine","Behavioral: Acute phase cognitive therapy"]}],"interventions":[{"name":"Continuation phase cognitive therapy","otherNames":[]},{"name":"Continuation phase fluoxetine","otherNames":["Prozac"]},{"name":"Continuation phase pill placebo","otherNames":[]},{"name":"Acute phase cognitive therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Recurrent unipolar major depressive disorder\n* Have experienced at least two episodes of major depression\n* Have experienced at least one period of recovery during a depressive episode or have a history of dysthymia (a mood disorder characterized by depression) prior to the onset of current or past depressive episodes\n* Willing and able to comply with all study requirements\n* Able to speak and read English\n\nExclusion Criteria:\n\n* Active alcohol or other substance dependence within 6 months prior to study entry\n* Currently at risk for suicide\n* Mood disorders due to a medical condition or substance abuse\n* Bipolar, schizoaffective, obsessive compulsive, or eating disorders\n* Schizophrenia\n* Unable to stop mood-altering medications\n* Current use of medication or diagnosis of a medical disorder that may cause depression (e.g., diabetes, head injury, stroke, cancer, multiple sclerosis)\n* Previous failure to experience a reduction in depressive symptoms after 8 weeks of cognitive therapy with a certified therapist\n* Previous failure to experience a reduction in depressive symptoms after 6 weeks of 40 mg of Prozac\n* Pregnancy or plan to become pregnant in the next 11-12 months\n* Unable to attend clinic twice weekly during business hours\n* Unable to complete questionnaires","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Depressive Relapse or MDD","description":"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment\n\nLIFE-PSR Scale:\n\n1. = No residual symptoms, no current evidence of the disorder.\n2. = Mild symptoms\n3. = Considerably less psychopathology than full criteria with no more than moderate impairment\n4. = Does not meet full criteria but has major symptoms of impairment\n5. = Meets criteria without extreme impairment in functioning\n6. = Meets criteria with extreme impairment in functioning\n\nThe relapse rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18.3","spread":null},{"groupId":"OG002","value":"32.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Depressive Relapse/Recurrence or MDD","description":"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment\n\nLIFE-PSR Scale:\n\n1. = No residual symptoms, no current evidence of the disorder.\n2. = Mild symptoms\n3. = Considerably less psychopathology than full criteria with no more than moderate impairment\n4. = Does not meet full criteria but has major symptoms of impairment\n5. = Meets criteria without extreme impairment in functioning\n6. = Meets criteria with extreme impairment in functioning\n\nRelapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"35.0","spread":null},{"groupId":"OG002","value":"42.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Depressive Relapse/Recurrence or MDD","description":"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment\n\nLIFE-PSR Scale:\n\n1. = No residual symptoms, no current evidence of the disorder.\n2. = Mild symptoms\n3. = Considerably less psychopathology than full criteria with no more than moderate impairment\n4. = Does not meet full criteria but has major symptoms of impairment\n5. = Meets criteria without extreme impairment in functioning\n6. = Meets criteria with extreme impairment in functioning\n\nRelapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"45.2","spread":null},{"groupId":"OG002","value":"56.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":86},"commonTop":[]}}}